ZL006 | ZL-006 | CAS#1181226-02-7 | PSD95-nNOS inhibitor

MedKoo Cat#: 526933 | Name: ZL006

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ZL006 is a PSD95-nNOS protein-protein interaction inhibitor. ZL006 (EC50: 12.88 μM) directly inhibited binding of purified PSD95 and nNOS proteins in AlphaScreen without altering binding of PSD95 to ErbB4. ZL006 preferentially suppressed phase 2A pain behavior in the formalin test and suppressed allodynia induced by intraplantar complete Freund's adjuvant administration. Disrupting PSD95-nNOS protein-protein interactions is effective in attenuating pathological pain without producing unwanted side effects (i.e. motor ataxia) associated with NMDAR antagonists. (

Chemical Structure

ZL006

CAS#1181226-02-7

Theoretical Analysis

MedKoo Cat#: 526933

Name: ZL006

CAS#: 1181226-02-7

Chemical Formula: C14H11Cl2NO4

Exact Mass: 327.0065

Molecular Weight: 328.15

Elemental Analysis: C, 51.24; H, 3.38; Cl, 21.61; N, 4.27; O, 19.50

Price and Availability

Size	Price	Availability
25mg	USD 250.00	2 Weeks
50mg	USD 450.00	2 Weeks
100mg	USD 750.00	2 Weeks
1g	USD 3,250.00	2 Weeks
2g	USD 5,850.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

ZL006; ZL-006; ZL 006.

IUPAC/Chemical Name

4-(3,5-Dichloro-2-hydroxy-benzylamino)-2-hydroxybenzoic acid

InChi Key

RTEYSQSXRFVKTJ-UHFFFAOYSA-N

InChi Code

InChI=1S/C14H11Cl2NO4/c15-8-3-7(13(19)11(16)4-8)6-17-9-1-2-10(14(20)21)12(18)5-9/h1-5,17-19H,6H2,(H,20,21)

SMILES Code

O=C(O)C1=CC=C(NCC2=CC(Cl)=CC(Cl)=C2O)C=C1O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 328.15 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Song J, Zeng J, Chen X, Wang J, Zhang Y, Gao Y, Wang R, Jiang N, Lin Y, Li R. Anti-neuroinflammatory agent rhein lysinate-based self-assembled injectable hydrogel loaded with ZL006 for promoting post-stroke functional recovery. Biomaterials. 2025 Jan 23;318:123124. doi: 10.1016/j.biomaterials.2025.123124. Epub ahead of print. PMID: 39884131. 2: Liu Y, Yao Y, Fang W, Wang X, Lu W. Combinatorial therapy with sub-effective Ro25-6981 and ZL006 ameliorates depressive-like behavior in single or combined stressed male mice. Biochem Biophys Res Commun. 2024 Oct 20;730:150385. doi: 10.1016/j.bbrc.2024.150385. Epub 2024 Jul 10. PMID: 39002200. 3: Zhang Q, Li S, Chen H, Yin J, Chen Y, Liu L, He W, Min Z, Gong Y, Xu J, Song K, Lv W, Xin H. Reduction of Oxidative Stress and Excitotoxicity by Mesenchymal Stem Cell Biomimetic Co-Delivery System for Cerebral Ischemia-Reperfusion Injury Treatment. Small. 2024 Oct;20(43):e2401045. doi: 10.1002/smll.202401045. Epub 2024 Jul 1. PMID: 38948959. 4: Zhao L, Qu HL, Zhang Y, Wu X, Ji QX, Zhang Z, Li D. ZL006 mitigates anxiety- like behaviors induced by closed head injury through modulation of the neural circuit from the medial prefrontal cortex to amygdala. Cereb Cortex. 2024 Jun 4;34(6):bhae237. doi: 10.1093/cercor/bhae237. PMID: 38850218. 5: Wu H, Huang Z, Wang X, Chen M, Chen W, Hua Y, Ren J, Shen L, Song Y, Zhou Y, Luo C, Lin Y, Wang Y, Chang L, Li F, Zhu D. Preclinical evaluation of ZL006-05, a new antistroke drug with fast-onset antidepressant and anxiolytic effects. Stroke Vasc Neurol. 2023 Dec 29;8(6):463-474. doi: 10.1136/svn-2022-002156. PMID: 37185136; PMCID: PMC10800258. 6: Chen ZJ, Su CW, Xiong S, Li T, Liang HY, Lin YH, Chang L, Wu HY, Li F, Zhu DY, Luo CX. Enhanced AMPAR-dependent synaptic transmission by S-nitrosylation in the vmPFC contributes to chronic inflammatory pain-induced persistent anxiety in mice. Acta Pharmacol Sin. 2023 May;44(5):954-968. doi: 10.1038/s41401-022-01024-z. Epub 2022 Dec 2. PMID: 36460834; PMCID: PMC10104852. 7: Wang SN, Wang Z, Wang XY, Zhang XP, Xu TY, Miao CY. Humanized cerebral organoids-based ischemic stroke model for discovering of potential anti-stroke agents. Acta Pharmacol Sin. 2023 Mar;44(3):513-523. doi: 10.1038/s41401-022-00986-4. Epub 2022 Sep 13. PMID: 36100766; PMCID: PMC9958103. 8: Oliva I, Saberi SA, Rangel-Barajas C, Iyer V, Bunner KD, Lai YY, Kulkarni PM, Garai S, Thakur GA, Crystal JD, Rebec GV, Hohmann AG. Inhibition of PSD95-nNOS protein-protein interactions decreases morphine reward and relapse vulnerability in rats. Addict Biol. 2022 Sep;27(5):e13220. doi: 10.1111/adb.13220. PMID: 36001441; PMCID: PMC9539577. 9: Zeng J, Su P, Li F, Yun Y, Liang H, Qu K, Fan Y, Zhang M, Song J, Yao Y, Shen H, Jiang N, Li R, Zhu D. An Injectable Hydrogel for Treatment of Chronic Neuropathic Pain. Macromol Biosci. 2022 Jun;22(6):e2100529. doi: 10.1002/mabi.202100529. Epub 2022 Apr 14. PMID: 35362658. 10: Wei W, Liu W, Du S, Govindarajalu G, Irungu A, Bekker A, Tao YX. A Compound Mitigates Cancer Pain and Chemotherapy-Induced Neuropathic Pain by Dually Targeting nNOS-PSD-95 Interaction and GABAA Receptor. Neurotherapeutics. 2021 Oct;18(4):2436-2448. doi: 10.1007/s13311-021-01158-8. Epub 2021 Nov 18. PMID: 34796458; PMCID: PMC8804143. 11: Yang L, Cui J, Zeng L, Lu W. Targeting PSD95/nNOS by ZL006 alleviates social isolation-induced heightened attack behavior in mice. Psychopharmacology (Berl). 2022 Jan;239(1):267-276. doi: 10.1007/s00213-021-06000-9. Epub 2021 Oct 18. PMID: 34661719; PMCID: PMC8521491. 12: Fan XM, Ren YF, Fu X, Wu H, Ye X, Jiang YF, You FM. Gabapentin has Longer- Term Efficacy for the Treatment of Chronic Pelvic Pain in Women: A Systematic Review and Pilot Meta-analysis. Pain Ther. 2021 Dec;10(2):1673-1689. doi: 10.1007/s40122-021-00330-4. Epub 2021 Oct 4. PMID: 34606030; PMCID: PMC8586286. 13: Li J, Zhang L, Xu C, Shen YY, Lin YH, Zhang Y, Wu HY, Chang L, Zhang YD, Chen R, Zhang ZP, Luo CX, Li F, Zhu DY. A pain killer without analgesic tolerance designed by co-targeting PSD-95-nNOS interaction and α2-containning GABAARs. Theranostics. 2021 Apr 3;11(12):5970-5985. doi: 10.7150/thno.58364. PMID: 33897893; PMCID: PMC8058733. 14: Ren YF, Fu X, Wang YT, Liu H, Zheng XZ, Liu J, Li LJ, You FM. Nalbuphine Versus Ketorolac as an Adjuvant to Local Wound Infiltration Anesthesia in Open Colorectal Surgery: A Prospective Randomized Controlled Study. Pain Ther. 2021 Jun;10(1):551-565. doi: 10.1007/s40122-021-00246-z. Epub 2021 Feb 24. PMID: 33629263; PMCID: PMC8119574. 15: Li W, Guo J, Wang Q, Tang J, You F. The efficacy of Chinese herbal medicine as an adjunctive therapy for colorectal cancer: A protocol for systematic review of randomized controlled trials. Medicine (Baltimore). 2020 Dec 18;99(51):e23216. doi: 10.1097/MD.0000000000023216. PMID: 33371062; PMCID: PMC7748206. 16: Tao WY, Yu LJ, Jiang S, Cao X, Chen J, Bao XY, Li F, Xu Y, Zhu XL. Neuroprotective effects of ZL006 in Aβ1-42-treated neuronal cells. Neural Regen Res. 2020 Dec;15(12):2296-2305. doi: 10.4103/1673-5374.285006. PMID: 32594052; PMCID: PMC7749460. 17: Kou XL, Tao Y, Xian JY, Lin YH, Cai CY, Wu HY, Chang L, Zhu DY. Uncoupling nNOS-PSD-95 in mPFC inhibits morphine priming-induced reinstatement after extinction training. Biochem Biophys Res Commun. 2020 Apr 30;525(2):520-527. doi: 10.1016/j.bbrc.2020.02.112. Epub 2020 Feb 26. PMID: 32113678. 18: Qu W, Liu NK, Wu X, Wang Y, Xia Y, Sun Y, Lai Y, Li R, Shekhar A, Xu XM. Disrupting nNOS-PSD95 Interaction Improves Neurological and Cognitive Recoveries after Traumatic Brain Injury. Cereb Cortex. 2020 Jun 1;30(7):3859-3871. doi: 10.1093/cercor/bhaa002. PMID: 31989159; PMCID: PMC7264644. 19: Song S, Lee J, Park S, Choi S. Fear renewal requires nitric oxide signaling in the lateral amygdala. Biochem Biophys Res Commun. 2020 Feb 26;523(1):86-90. doi: 10.1016/j.bbrc.2019.12.038. Epub 2019 Dec 9. PMID: 31831176. 20: Zhang L, Luan H, Lu W, Wang H. Preformulation Studies and Enabling Formulation Selection for an Insoluble Compound at Preclinical Stage-From In Vitro, In Silico to In Vivo. J Pharm Sci. 2020 Feb;109(2):950-958. doi: 10.1016/j.xphs.2019.10.023. Epub 2019 Oct 21. PMID: 31647952.